2024-10-06 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and markets a wide range of medicines.

**1. Performance vs. S&P 500:**

* **Cumulative Return:** ABBV has a cumulative return of 154.04%, compared to 131.01% for the S&P 500 (VOO).
* **Outperformance:** ABBV has outperformed the S&P 500 by 23.03%. This places it at the 63.95th percentile of its historical outperformance range, indicating a relatively strong performance compared to its past.

**2. Recent Price Action:**

* **Closing Price:** $195.45
* **5-Day Moving Average:** $196.36
* **20-Day Moving Average:** $194.67
* **60-Day Moving Average:** $189.40

The current price is slightly below the 5-day moving average, suggesting potential short-term weakness. However, it remains above both the 20-day and 60-day moving averages, indicating potential longer-term bullish momentum.

**3. Technical Indicators:**

* **RSI:** 53.5 - This indicates a neutral to slightly overbought market, suggesting potential for a pullback.
* **PPO:** -0.0 - This indicates a neutral market, with no clear trend direction.
* **Delta_Previous_Relative_Divergence:** -3.81 - This indicates short-term downward momentum in relative price performance.
* **Expected Return:** 0.9% - This suggests a potential 5-year return exceeding the S&P 500 by 0.9% if current trends continue.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

AbbVie has consistently exceeded earnings expectations in recent quarters. The latest earnings report for Q2 2024 shows EPS of $2.65, exceeding expectations of $2.57. This strong performance reflects the company's ability to deliver consistent growth in core businesses like Humira. However, the future earnings outlook is uncertain, given the potential impact of new biosimilars entering the market for Humira.

**5. News and Recent Issues:**

* **Recent Market Outlook:** AbbVie's stock has been relatively stable in recent months, with some volatility tied to news surrounding its blockbuster drug Humira, facing biosimilar competition. 
* **Analyst Opinions:**  Analysts generally hold a positive outlook on ABBV. Many have maintained "Buy" or "Outperform" ratings, citing its strong dividend yield, diversified portfolio, and potential for growth in new therapies.
* **Performance Highlights:** AbbVie's stock has been a consistent performer over the long term, with a solid track record of dividend increases and revenue growth. However, concerns remain about the future impact of biosimilar competition on Humira's sales.

**6. Summary:**

* AbbVie has outperformed the S&P 500 over the long term, with a solid history of exceeding earnings expectations.
* Current technical indicators suggest neutral to slightly overbought conditions, with some short-term weakness.
* The company's long-term growth outlook is uncertain, influenced by the impact of biosimilar competition on Humira.
* Despite these concerns, AbbVie remains a strong company with a diversified portfolio and potential for continued growth.
* Analysts remain largely positive on the stock, citing its attractive dividend yield and ongoing pipeline development.

**7. Conclusion:**

AbbVie is a well-established biopharmaceutical company with a strong track record of performance. Despite the potential impact of biosimilar competition on Humira, the company has a diversified portfolio and a promising pipeline of new therapies. The stock's current valuation appears reasonable, with potential for further growth. However, investors should remain mindful of the risks associated with its dependence on Humira and the competitive landscape in the biopharmaceutical industry.